These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 18474790)

  • 21. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
    Aihara M; Oshima H; Araie M;
    Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients.
    Martinez A; Sanchez M
    Eye (Lond); 2009 Apr; 23(4):810-8. PubMed ID: 18535605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
    Alm A; Grunden JW; Kwok KK
    J Glaucoma; 2011; 20(4):215-22. PubMed ID: 20520568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension.
    Ge J; Sun XH; Wang NL; Zhao JL; Wu LL; Chen XM; Wang ZX; Li B
    Chin Med J (Engl); 2010 Jun; 123(11):1417-21. PubMed ID: 20819599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.
    Choplin N; Bernstein P; Batoosingh AL; Whitcup SM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S19-25. PubMed ID: 15016558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost.
    Nakakura S; Tabuchi H; Kiuchi Y
    Optom Vis Sci; 2011 Sep; 88(9):1140-4. PubMed ID: 21666524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma.
    How AC; Kumar RS; Chen YM; Su DH; Gao H; Oen FT; Ho CL; Seah SK; Aung T
    Br J Ophthalmol; 2009 Jun; 93(6):782-6. PubMed ID: 19336424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Topical prostaglandins influence over cornea--preliminary report].
    Wierzbowska J; Stankiewicz A
    Klin Oczna; 2006; 108(10-12):479-81. PubMed ID: 17455732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accounting for restart rates in evaluating persistence with ocular hypotensives.
    Schwartz GF; Platt R; Reardon G; Mychaskiw MA
    Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe.
    Holló G; Thelen U; Teus MA; Quaranta L; Ferkova S; Babić N; Misiuk-Hojlo M; Mikropoulos DG; Kaluzny BJ; Kozobolis V; Januleviciene I; Kóthy P; Camara C; Russo A; Krzyzanowska-Berkowska P; Cieślińska I; Stewart JA; Kristoffersen MS; Nelson LA; Stewart WC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):493-8. PubMed ID: 21790326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do prostaglandin analogs affect eyelid position and motility?
    Altieri M; Ferrari E
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):511-7. PubMed ID: 21767139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies.
    Dams I; Wasyluk J; Prost M; Kutner A
    Prostaglandins Other Lipid Mediat; 2013; 104-105():109-21. PubMed ID: 23353557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Migraine headache associated with latanoprost.
    Weston BC
    Arch Ophthalmol; 2001 Feb; 119(2):300-1. PubMed ID: 11176999
    [No Abstract]   [Full Text] [Related]  

  • 37. Analysis of 24-Hour IOP-related Pattern Changes After Medical Therapy.
    Holló G; Kóthy P; Vargha P
    J Glaucoma; 2015; 24(5):397-8. PubMed ID: 25774946
    [No Abstract]   [Full Text] [Related]  

  • 38. Analysis of 24-Hour IOP-related Pattern Changes After Medical Therapy.
    Mansouri K; Medeiros FA; Liu JH; De Moraes CG; Weinreb RN
    J Glaucoma; 2015; 24(5):396. PubMed ID: 25850970
    [No Abstract]   [Full Text] [Related]  

  • 39. Lower eyelid melanoma during bimatoprost (Lumigan) therapy.
    Sun LL; Welch RT; Vu P
    Clin Exp Ophthalmol; 2012 Mar; 40(2):213-4. PubMed ID: 22004163
    [No Abstract]   [Full Text] [Related]  

  • 40. Hypertrichosis of the upper cheek area associated with travoprost treatment of glaucoma.
    Ortiz-Perez S; Olver JM
    Ophthalmic Plast Reconstr Surg; 2010; 26(5):376-7. PubMed ID: 20622697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.